NFKB1 and type 2 diabetes mellitus: In contrast, Myr treatment significantly suppressed NF-κB activation in the renal cells in the diabetic milieu, and thus prevented renal inflammation evidenced by the reduction in IL-1β, IL-6, and TNF-α levels in the kidneys and C-reactive protein in the sera of T2D rats.